Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
World leaders, rights groups react to COP30 climate deal - 2Dominating the Remote Work Way of life: Individual Systems
- 3Audits of the Top Science fiction Movies This Year
- 4The Most Compelling Innovation Advancements Somewhat recently
- 5Mars orbiter sees 'butterfly' crater spread its wings on the Red Planet
- We may have one thing in common with jellyfish, new research finds
- 5 Critical Rules For Business Regulation Chiefs
- Knesset sets special panel to fast-track Karhi’s communications reform
- Decrease in Home Buy Credits and Home loan Renegotiating Rates: An Outline of Latest things
- Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- Somaliland denies trading recognition with Israel for accepting Gazans
- 5 Home Improvement Styles: Decision in favor of Your #1
- CDC studies show value of nationwide wastewater disease surveillance, as potential funding cut looms
- Struggling to keep your New Year's resolutions? Here's how to keep yourself on track
